WAVEMAN · COMPANY

ZBIO · Zenas Biopharma, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ZBIO

Name: Zenas BioPharma, Inc. (ZBIO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Zenas BioPharma, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001953926

CLUSTER · 3 INSIDERSACTIVIST 13DC-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

$7.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+100.0%

XBRL, annual

NET MARGIN

-3777.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$7.7M over 180 days

more than 95% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

88 funds added or opened last quarter

more than 61% of Pharma & Biotech

REVENUE

+100.0% year over year

more than 85% of Pharma & Biotech

MARGIN

-3777.4% net margin

below 96% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders bought a net $7.7M, but 1 Form 144 notice ($31.9M) are queued to sell.

88 funds added or opened positions in the latest 13F quarter, of 147 holders.

MOULDER LEON O JR disclosed a 5%+ stake (5.09%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +87.7%

+87.7%12M

INSIDER BUY13D/G STAKEFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $7.7M bought by insiders over 180 days, 88 funds added last quarter, $31.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Zenas BioPharma, Inc. insiders bought a net $7.7M of stock across 45 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

MOULDER LEON O JR

Chief Executive Officer

BUY

2026-05-18

60,000.0

$1.0M

MOULDER LEON O JR

Chief Executive Officer

BUY

2026-04-29

35,000.0

$616.7K

MOULDER LEON O JR

Chief Executive Officer

BUY

2026-04-28

25,000.0

$450.5K

MOULDER LEON O JR

Chief Executive Officer

BUY

2026-03-31

34,000.0

$656.5K

Lu Hongbo

Director

BUY

2026-03-31

75,000.0

$1.5M

45 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 40 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

9,506,701.0 sh

$241.3M

SR One Capital Management, LP

5,037,854.0 sh

$127.9M

NEA Management Company, LLC

4,023,219.0 sh

$102.1M

ENAVATE SCIENCES GP, LLC

3,919,159.0 sh

$99.5M

FEDERATED HERMES, INC.

3,116,805.0 sh

$79.1M

5%+ owners

13D = intent to influence · 13G = passive

MOULDER LEON O JR

ACTIVIST 13D · 2026-05-05

5.09%

Tellus BioVentures, LLC

ACTIVIST 13D · 2026-05-05

2.9%

Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008

ACTIVIST 13D · 2026-05-05

0.1%

Planned sales · Form 144

Filed before the sale — intent, not a trade

Zebra Aggregator, LP

FILED 2026-08-19

$31.9M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ALPS Medical Breakthroughs ETF

$1.3M POSITION · AS OF 2026-02-28

0.9%

Meridian Contrarian Fund

$4.8M POSITION · AS OF 2026-03-31

0.8%

Meridian Small Cap Growth Fund

$1.7M POSITION · AS OF 2026-03-31

0.7%

Invesco Dorsey Wright Healthcare Momentum ETF

$766.6K POSITION · AS OF 2026-04-30

0.6%

Fidelity Advisor Biotechnology Fund

$11.8M POSITION · AS OF 2026-04-30

0.6%

Federated Hermes Kaufmann Small Cap Fund

$17.3M POSITION · AS OF 2026-04-30

0.6%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12
REVENUE	$10.0M	$5.0M	$50.0M
OPERATING INCOME	$-383.1M	$-163.9M	$-37.1M
NET INCOME	$-377.7M	$-157.0M	$-37.1M
EPS (DILUTED)	-8.44	-11.89	-24.25
OPERATING CASH FLOW	$-172.3M	$-119.7M	$-30.5M
CASH	$110.6M	$319.7M	$56.9M
LONG-TERM DEBT	$78.6M	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE